China Hepatitis A Virus Vaccine For Children And Adult Vaccination Manufacturer, Supplier, Factory

AIM Action Biopharmaceutical Co., Ltd. supplies Hepatitis A Virus Vaccine For Children And Adult Vaccination based on human diploid cell culture technology. The product is designed for hepatitis A prevention by stimulating the body to develop immunity against hepatitis A virus after vaccination. For procurement organizations, vaccination programs, and healthcare providers, selecting a vaccine with clear age-specific dosage information and established manufacturing technology is essential for maintaining consistent immunization services.

Hepatitis A is an infectious disease caused by hepatitis A virus (HAV), which mainly affects the liver. The virus belongs to the Picornaviridae family and contains a single-stranded positive-sense RNA genome. Understanding the characteristics of HAV helps healthcare organizations select appropriate preventive solutions and develop effective immunization strategies.

Product Overview

The product is an inactivated hepatitis A vaccine developed using human diploid cell technology. During manufacturing, the hepatitis A virus Lv-8 strain is cultured in the KMB17 human diploid cell line, followed by virus harvesting, purification, concentration, and inactivation procedures to prepare the final vaccine product. This manufacturing approach helps maintain antigen characteristics while removing the replication ability of the virus.

For vaccination programs covering different age groups, product selection usually requires consideration of dosage, administration schedule, storage conditions, and population requirements. AIM’s hepatitis A vaccine portfolio includes formulations designed for pediatric and adult applications.

Structure of hepatitis A virus

Technology Advantages

The production technology behind this vaccine focuses on the use of human diploid cell substrates and controlled inactivation processes. Compared with vaccine selection based only on product name or dosage, professional purchasers usually pay more attention to manufacturing background, strain characteristics, and production consistency.

The main technical features include:

1. Human diploid cell platform: The vaccine uses KMB17 human diploid cell line as the culture substrate. This cell line was independently established by the Kunming Institute in 1974 and has been validated over a long period.

2. Lv-8 strain application: The Lv-8 strain was isolated and screened by the Kunming Institute during the 1988 Shanghai hepatitis A outbreak. According to the provided product information, this strain has characteristics including stable properties, high virus yield, short replication cycle, and good immunogenicity.

3. Inactivation process: After virus cultivation and purification, formaldehyde solution is added for inactivation to produce the final active pharmaceutical ingredient used in the vaccine.

Age Group Selection

Different age groups have different dosage requirements. For vaccination suppliers and healthcare institutions, accurate differentiation between pediatric and adult formulations helps improve vaccination management and reduce administration errors.

The product application includes:

1. Pediatric vaccination: The children's dosage is designed for individuals aged 1-15 years old, including those who are 15 years old. The single human dose is 0.5ml, containing 320 EU of hepatitis A virus antigen.

2. Adult vaccination: The adult dosage is designed for individuals over 15 years old (excluding 15 years old). The single human dose is 1.0ml, containing 640 EU of hepatitis A virus antigen.

3. Routine immunization support: Healthcare organizations can select suitable dosage forms according to target populations and vaccination requirements.

Dosage Information

The recommended immunization procedure should follow professional vaccination guidance. According to the provided product information, individuals aged 1-15 years old receive a primary immunization dose of 0.5ml followed by a booster dose after 6 months. Individuals over 15 years old receive a primary immunization dose of 1.0ml followed by a booster dose after 6 months.

Quality Control

For vaccine procurement, quality management throughout the manufacturing process is one of the key factors considered by medical institutions and immunization organizations. AIM Action Biopharmaceutical Co., Ltd. has established vaccine production capabilities based on pharmaceutical manufacturing requirements and continues to focus on vaccine research, development, and production management.

The hepatitis A vaccine production process includes multiple controlled steps, from virus culture and harvesting to purification and inactivation. These procedures are designed to ensure consistency of the final product and maintain the required antigen characteristics.

The quality-related features include:

1. Controlled production process: The vaccine is produced through standardized procedures including virus cultivation, purification, concentration, and inactivation.

2. Established manufacturing background: AIM Action has developed production lines for inactivated hepatitis A vaccine (human diploid cell) and obtained relevant NMPA approvals and GMP certification information for the product.

3. Professional vaccine development: AIM Vaccine operates multiple vaccine manufacturing enterprises and research platforms, focusing on vaccine research, development, and production.

Immune Response

The purpose of vaccination is to stimulate the body's immune system to recognize hepatitis A virus and develop protective immunity. The immune response generated after vaccination is an important consideration for healthcare providers when selecting hepatitis A prevention products.

According to the provided product information, AIM Action hepatitis A inactivated vaccine has demonstrated good immune effects in both children and adults. The antibody conversion rate is similar to imported hepatitis A inactivated vaccines, while the geometric mean titer (GMT) of antibodies is better than that of imported hepatitis A inactivated vaccines.

Application Areas

Hepatitis A vaccination plays an important role in public health prevention. For organizations managing vaccination services, selecting a product suitable for different age groups helps support broader immunization coverage.

Hepatitis A Virus Vaccine For Children And Adult Vaccination can be considered for:

1. Children's immunization: Pediatric vaccination programs require accurate dosage management and appropriate scheduling. The children's formulation supports vaccination needs for individuals aged 1-15 years old.

2. Adult vaccination: Adult vaccination programs require formulations with suitable antigen content and clear administration guidance.

3. Public health prevention: Healthcare organizations and vaccination providers can use hepatitis A vaccines as part of disease prevention strategies.

Storage And Packaging

Proper storage and transportation conditions are important for maintaining vaccine quality during distribution. According to the product information provided by AIM Action, the vaccine should be stored and shipped at 2-8℃ and protected from light.

The available packaging formats include:

1. Prefilled syringe: Designed for convenient administration and handling.

2. Vial packaging: Available according to different product specifications.

3. Validity period: The product validity period is 36 months according to the provided product information.

Why Work With AIM

Choosing a vaccine supplier requires more than checking product specifications. Procurement teams also need to evaluate manufacturing experience, technical capability, and long-term supply reliability.

AIM Honesty Biopharmaceutical Co., Ltd. is part of AIM Vaccine's vaccine manufacturing network. AIM Vaccine focuses on vaccine development and manufacturing and currently provides multiple human vaccine products, including hepatitis A vaccine (human diploid cell), inactivated products.

The company has established manufacturing enterprises and research platforms to support vaccine development and production management. This background provides professional buyers with additional confidence when evaluating vaccine suppliers.

FAQ

Q: What is hepatitis A vaccine used for?

A: Hepatitis A vaccine is used to stimulate immunity against hepatitis A virus. After vaccination, the body can develop an immune response to help prevent hepatitis A infection.

Q: Who can receive this vaccine?

A: According to the provided product information, the vaccine is suitable for susceptible individuals. Different dosage specifications are available for children aged 1-15 years old and adults over 15 years old.

Q: What is the difference between pediatric and adult dosage?

A: The pediatric dosage is 0.5ml per dose containing 320 EU of hepatitis A virus antigen. The adult dosage is 1.0ml per dose containing 640 EU of hepatitis A virus antigen.

Q: How should the vaccine be administered?

A: The vaccine should be shaken well before use and administered by intramuscular injection at the deltoid muscle attachment site on the outer side of the upper arm according to professional vaccination guidance.

Q: What storage conditions are required for this product?

A: According to the provided product information, the vaccine should be stored and shipped at 2-8℃ and protected from light to maintain product quality.

Q: Why choose a human diploid cell based hepatitis A vaccine?

A: Human diploid cell technology provides a well-established production platform. The vaccine uses the KMB17 human diploid cell line and the Lv-8 hepatitis A virus strain with controlled cultivation and purification procedures.